News - Allergan

Filter

Current filters:

Allergan

Popular Filters

1 to 25 of 50 results

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

Allergan rejects Valeant’s latest bid

Allergan rejects Valeant’s latest bid

24-06-2014

Botox maker Allergan has announced that its Board of Directors has unanimously determined that Valeant…

AllerganBusiness FinanceBusiness FinanceEconomicsFinanceMergers & AcquisitionsPharmaceuticalStock marketUSAValeant Pharmaceuticals

Valeant goes hostile in $53 billion bid for Allergan

Valeant goes hostile in $53 billion bid for Allergan

18-06-2014

Canada’s Valeant Pharmaceuticals International has today commenced an exchange offer for the common…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Pershing Square files law suit over Allergan’s rights plan

Pershing Square files law suit over Allergan’s rights plan

15-06-2014

William Ackman's Pershing Square Capital Management has filed a law suit in the Delaware Court of Chancery…

AllerganLegalMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Allergan board again rejects revised unsolicited takeover bid from Valeant

Allergan board again rejects revised unsolicited takeover bid from Valeant

10-06-2014

US Botox-maker Allergan says that its board of directors, after consulting with its independent financial…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Valeant goes even further, upping recently sweetened offer for Allergan

Valeant goes even further, upping recently sweetened offer for Allergan

02-06-2014

Even before it received an official response from its takeover target US Botox-maker Allergan, acquisitive…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Allergan board totally rejects Valeant’s $46 billion bid

Allergan board totally rejects Valeant’s $46 billion bid

13-05-2014

USA-based Allergan said yesterday that its board of directors has unanimously rejected the $46 billion…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Takeover target Allergen reports strong 1st-qtr sales growth

07-05-2014

US drugmaker Allergan reported a strong set of first-quarter 2014 financial results, with global sales…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Allergan adopts stockholder rights plan

23-04-2014

USA-based Allergan, the subject of a hostile takeover bid from Canada’s Valeant Pharmaceuticals reported…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Valeant joins with hedge fund in $45.6 billion unsolicited bid for Allergan

22-04-2014

Canada’s Valeant Pharmaceuticals International, never shy to go for hostile takeover moves, says it…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Allergan faces law suit alleging payment of kickbacks to optometrists to prescribe Restasis

Allergan faces law suit alleging payment of kickbacks to optometrists to prescribe Restasis

14-02-2014

US drugmaker Allergan (NYSE: AGN) is the subject of legal action after allegations that it paid kickbacks…

AllerganLegalOphthalmicsPharmaceuticalRestasisUSA

UK’s MHRA approves Botox for treatment of ankle disability in stroke survivors

04-02-2014

Allergan says that Botox has been approved by the UK’s Medicines and Healthcare Products Regulatory…

AllerganBotoxPharmaceuticalRegulationUK

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

Allergan closes $65 million deal with Medytox

Allergan closes $65 million deal with Medytox

09-01-2014

This week US drugmaker Allergan (NYSE: AGN) announced that it has closed a $65 million license agreement…

AllerganAsia-PacificBotoxDermatologicalsLicensingMedytoxPharmaceuticalRegulationUKUSA

Review of key drivers of migraine market growth through 2022

06-12-2013

Use of Allergan’s Botox (botulinum toxin type A) for the prophylactic treatment of chronic migraine…

AllerganAsia-PacificBotoxCoLucid PharmaceuticalsEuropelasmiditanLevadexMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Allergan reports 3rd-qtr sales rise of 12.9%, plans disposal

29-10-2013

US drugmaker Allergan has posted a strong set of financial results for the third quarter of 2013, with…

AllerganFinancialMergers & Acquisitions

Allergan and Medytox collaborate on neurotoxins

28-09-2013

Allergan has entered into a license agreement with Medytox which will see Allergan pay Medytox $65 million…

AllerganGlobalLicensingMedytoxPharmaceuticalResearch

UK MHRA licenses Allergan's Botox for use in patients with overactive bladder

11-09-2013

Botox (botulinum toxin type A), from US drugmaker Allergan (NYSE: AGN), has been licensed by the UK Medicines…

AllerganBotoxEuropeGenito-urinaryPharmaceuticalRegulation

Two more drug patents revoked in India

12-08-2013

In another blow for intellectual property in India, local drugmaker Ajanta Pharma has prevailed in revoking…

Ajanta PharmaAllerganAsia-PacificCombiganGanfortGenericsOphthalmicsPatentsPharmaceutical

India's NPPA says drugmakers cannot raise prices of imported products

10-05-2013

At a meeting earlier this month, India's drug price regulator the National Pharmaceutical Pricing Authority…

AllerganAsia-PacificNovartisPharmaceuticalPricingSanofi

FDA sends CRL rejecting Allergan's migraine drug Levadex on quality issues

17-04-2013

US drugmaker Allergan (NYSE: AGN) said yesterday (April 16) that the US Food and Drug Administration…

AllerganLevadexNeurologicalNorth AmericaPharmaceuticalProductionRegulation

1 to 25 of 50 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top